189 related articles for article (PubMed ID: 11278845)
41. Differences in the longevity of topo IIalpha and topo IIbeta drug-stabilized cleavable complexes and the relationship to drug sensitivity.
Errington F; Willmore E; Leontiou C; Tilby MJ; Austin CA
Cancer Chemother Pharmacol; 2004 Feb; 53(2):155-62. PubMed ID: 14504921
[TBL] [Abstract][Full Text] [Related]
42. Cross-resistance of an amsacrine-resistant human leukemia line to topoisomerase II reactive DNA intercalating agents. Evidence for two topoisomerase II directed drug actions.
Zwelling LA; Mayes J; Hinds M; Chan D; Altschuler E; Carroll B; Parker E; Deisseroth K; Radcliffe A; Seligman M
Biochemistry; 1991 Apr; 30(16):4048-55. PubMed ID: 1850298
[TBL] [Abstract][Full Text] [Related]
43. Atypical multidrug resistance may be associated with catalytically active mutants of human DNA topoisomerase II alpha.
Okada Y; Tosaka A; Nimura Y; Kikuchi A; Yoshida S; Suzuki M
Gene; 2001 Jul; 272(1-2):141-8. PubMed ID: 11470519
[TBL] [Abstract][Full Text] [Related]
44. Estrogen-induced potentiation of DNA damage and cytotoxicity in human breast cancer cells treated with topoisomerase II-interactive antitumor drugs.
Epstein RJ; Smith PJ
Cancer Res; 1988 Jan; 48(2):297-303. PubMed ID: 2825970
[TBL] [Abstract][Full Text] [Related]
45. Stimulation of topoisomerase II-mediated DNA damage via a mechanism involving protein thiolation.
Wang H; Mao Y; Chen AY; Zhou N; LaVoie EJ; Liu LF
Biochemistry; 2001 Mar; 40(11):3316-23. PubMed ID: 11258951
[TBL] [Abstract][Full Text] [Related]
46. HT1080/DR4: a P-glycoprotein-negative human fibrosarcoma cell line exhibiting resistance to topoisomerase II-reactive drugs despite the presence of a drug-sensitive topoisomerase II.
Zwelling LA; Slovak ML; Doroshow JH; Hinds M; Chan D; Parker E; Mayes J; Sie KL; Meltzer PS; Trent JM
J Natl Cancer Inst; 1990 Oct; 82(19):1553-61. PubMed ID: 1976136
[TBL] [Abstract][Full Text] [Related]
47. Genotoxic effects of topoisomerase poisoning and PARP inhibition on zebrafish embryos.
Karapetian M; Tsikarishvili S; Kulikova N; Kurdadze A; Zaalishvili G
DNA Repair (Amst); 2020 Mar; 87():102772. PubMed ID: 31877465
[TBL] [Abstract][Full Text] [Related]
48. Probing the interaction of the cytotoxic bisdioxopiperazine ICRF-193 with the closed enzyme clamp of human topoisomerase IIalpha.
Patel S; Jazrawi E; Creighton AM; Austin CA; Fisher LM
Mol Pharmacol; 2000 Sep; 58(3):560-8. PubMed ID: 10953049
[TBL] [Abstract][Full Text] [Related]
49. Catalysis of ATP hydrolysis by two NH(2)-terminal fragments of yeast DNA topoisomerase II.
Olland S; Wang JC
J Biol Chem; 1999 Jul; 274(31):21688-94. PubMed ID: 10419479
[TBL] [Abstract][Full Text] [Related]
50. Dual functions of the homeoprotein DLX4 in modulating responsiveness of tumor cells to topoisomerase II-targeting drugs.
Trinh BQ; Ko SY; Barengo N; Lin SY; Naora H
Cancer Res; 2013 Jan; 73(2):1000-10. PubMed ID: 23222298
[TBL] [Abstract][Full Text] [Related]
51. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
52. On the structural basis and design guidelines for type II topoisomerase-targeting anticancer drugs.
Wu CC; Li YC; Wang YR; Li TK; Chan NL
Nucleic Acids Res; 2013 Dec; 41(22):10630-40. PubMed ID: 24038465
[TBL] [Abstract][Full Text] [Related]
53. Measurement of Drug-Stabilized Topoisomerase II Cleavage Complexes by Flow Cytometry.
de Campos Nebel M; Palmitelli M; González-Cid M
Curr Protoc Cytom; 2017 Jul; 81():7.48.1-7.48.8. PubMed ID: 28678420
[TBL] [Abstract][Full Text] [Related]
54. Stability of the topoisomerase II closed clamp conformation may influence DNA-stimulated ATP hydrolysis.
Vaughn J; Huang S; Wessel I; Sorensen TK; Hsieh T; Jensen LH; Jensen PB; Sehested M; Nitiss JL
J Biol Chem; 2005 Mar; 280(12):11920-9. PubMed ID: 15647268
[TBL] [Abstract][Full Text] [Related]
55. Local base sequence preferences for DNA cleavage by mammalian topoisomerase II in the presence of amsacrine or teniposide.
Pommier Y; Capranico G; Orr A; Kohn KW
Nucleic Acids Res; 1991 Nov; 19(21):5973-80. PubMed ID: 1658748
[TBL] [Abstract][Full Text] [Related]
56. Phosphorylation of topoisomerase II by casein kinase II and protein kinase C: effects on enzyme-mediated DNA cleavage/religation and sensitivity to the antineoplastic drugs etoposide and 4'-(9-acridinylamino)methane-sulfon-m-anisidide.
DeVore RF; Corbett AH; Osheroff N
Cancer Res; 1992 Apr; 52(8):2156-61. PubMed ID: 1313738
[TBL] [Abstract][Full Text] [Related]
57. Stabilization of the topoisomerase II-DNA cleavage complex by antineoplastic drugs: inhibition of enzyme-mediated DNA religation by 4'-(9-acridinylamino)methanesulfon-m-anisidide.
Robinson MJ; Osheroff N
Biochemistry; 1990 Mar; 29(10):2511-5. PubMed ID: 2159323
[TBL] [Abstract][Full Text] [Related]
58. Increased ATP requirement for activity of and complex formation by DNA topoisomerase II from human leukemic CCRF-CEM cells selected for resistance to teniposide.
Danks MK; Schmidt CA; Deneka DA; Beck WT
Cancer Commun; 1989; 1(2):101-9. PubMed ID: 2561733
[TBL] [Abstract][Full Text] [Related]
59. Etoposide-induced DNA damage is increased in p53 mutants: identification of ATR and other genes that influence effects of p53 mutations on Top2-induced cytotoxicity.
Menendez D; Anand JR; Murphy CC; Bell WJ; Fu J; Slepushkina N; Buehler E; Martin SE; Lal-Nag M; Nitiss JL; Resnick MA
Oncotarget; 2022; 13():332-346. PubMed ID: 35178190
[TBL] [Abstract][Full Text] [Related]
60. Analysis of yeast DNA topoisomerase II mutants resistant to the antitumor drug amsacrine.
Wasserman RA; Wang JC
Cancer Res; 1994 Apr; 54(7):1795-800. PubMed ID: 8137294
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]